General Electric Co.

NYSE:GE  
64.56
-0.80 (-1.22%)
5:20:31 PM EDT: $64.94 +0.38 (+0.59%)
Products, Regulatory

GE Healthcare And Lantheus Phase III Clinical Trial Finds Flurpiridaz PET Radiotracer Could Improve Detection Of Coronary Artery Disease

Published: 09/13/2022 12:24 GMT
General Electric Co. (GE) - GE Healthcare and Lantheus Phase Iii Clinical Trial Finds 18fflurpiridaz Pet Radiotracer Could Improve Detection of Coronary Artery Disease.
GE - Phase Iii Clinical Trial of 18fflurpiridaz Pet Diagnostic Radiopharmaceutical Meets Co-primary Endpoints for Detecting Coronary Artery Disease.
GE - Trial Also Met Its First Key Secondary Endpoint, Demonstrating Higher Diagnostic Efficacy for 18fflurpiridaz Pet Compared to Spect Mpi.